COEP - שווי פעילות לרווח לפני ריבית, מסים ופחת Coeptis Therapeutics

Coeptis Therapeutics (COEP) is an oncology biotech that allocates resources to trials without generating profit, rendering its cash flow unpredictable. This EV/EBITDA chart reflects a value of 0.00. Business development relies on scientific alliances and patent leasing, as the company lacks the funds for acquisitions. Meanwhile, global conflicts and sanctions are hindering international trials and the delivery of biosamples.

For Coeptis Therapeutics (COEP), which is developing early-stage cell therapies without commercial products, this indicator compares the total enterprise value with operating profit before depreciation and interest. Analyzing changes in the EV/EBITDA multiple allows for the separation of speculative price growth from actual scaling, revealing the company's critical dependence on external financing amid negative cash flow.